Overview

Raised to Date: Raised: $583,204

Deal Terms

Investment Momentum

Company Profile

Deal Summary

Financials

Funding History

Growth Charts

Total Commitments ($USD)

Platform

StartEngine

Start Date

07/31/2022

Close Date

12/30/2022

Min. Goal

$9,997

Max. Goal

$2,898,856

Min. Investment

$489

Security Type

Equity - Common

Series

Series C

SEC Filing Type

RegCF    

Price Per Share

$5.69

Pre-Money Valuation

$230,180,296

Rolling Commitments ($USD)

Status

Funded

Reporting Date

12/31/2022

Days Remaining

Funded

% of Min. Goal

Funded

% of Max. Goal

Funded

Likelihood of Max

Funded

Avg. Daily Raise

$3,862

# of Investors

397

Momentum

Funded

Create a free account today to gain access to KingsCrowd analytics.

Logos provided by Clearbit

Koning

Year Founded

2002

Industry

Healthcare & Pharmaceuticals

Tech Sector

Medtech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Norcross, Georgia

Business Type

Growth

Company Website

Koning, with a valuation of $230 million, is raising funds on StartEngine. The company has developed a revolutionary breast imaging technology that offers real isotropic 3D imaging. The Koning Breast CT creates high-contrast 3D breast images with high spatial resolution without the painful compression of mammograms. Koning has received approvals from FDA PMA, CFDA, CE Mark, and other global regulators and is designed for highly accurate early detection of breast cancer. Dr. Ruola Ning founded Koning in January 2002. The current crowdfunding campaign has a minimum target of $9,997.33 and a maximum target of $2,898,855.85. The campaign proceeds will be used for growth and expansion.

Summary Profit and Loss Statement

	Most Recent Year	Prior Year
Revenue	$357,779	$3,089,624
COGS	$153,022	$417,340
Tax	$65	$5,085
Net Income	$-4,869,465	$-1,135,429

Summary Balance Sheet

	Most Recent Year	Prior Year
Cash	$522,412	$1,099,408
Accounts Receivable	$322,892	$777,636
Total Assets	$26,507,126	$27,843,270
Short-Term Debt	$3,768,501	$4,358,049
Long-Term Debt	$5,355,334	$5,198,730
Total Liabilities	$9,123,835	$9,556,779

Financials as of: 07/31/2022

Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name	Close Date	Platform	Valuation/Cap	Total Raised	Security Type	Status	Reg Type
Koning	12/29/2022	StartEngine	$230,180,296	$583,204	Equity - Common	Funded	RegCF
Koning	01/17/2022	Republic	$200,000,000	$2,135,386	SAFE	Funded	RegCF

Create a free account today to gain access to KingsCrowd analytics.

• Price per Share
• Valuation
• Revenue
• Employees

Price per Share Valuation Revenue Employees

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Koning’s machines can reliably detect stage 0 and stage 1 cancers. Just how significant is this? Detecting breast cancer at stages 0 or 1 gives patients a 99% five-year survival rate. Its imaging technology can also detect small calcifications and small tumors in patients with small or dense breasts — something current mammograms struggle with. Calcifications, by the way, are often an early indicator of breast disease.

This changes the game. Mammography has ruled the industry for 60 years. While flawed, it was — for its time — the best technology available. That’s no longer the case. 

Buy the Full Report